Podcasts about Proteus

ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ovation 2. MajesTEC-9 - 2L teclistamab in multiple myeloma in patient population 100% exposed to CD-38 targeting drugs 3. Initsmeran autogene + pembrolizumab in resected melanoma. Only a Phase 2 study, but super promising and exciting use of personalized medicine using mRNA technology 4. Libretto-043 - adjuvant selpercatinib in RET-fusion positive NSCLC following resection and platinum-based chemotherapy (in most of these patients) 5. PROTEUS - meh 6. SARC041 - Phase study of abemaciclib vs. placebo in dedifferntiated liposarcoma. The placebo did very poorly 7. CROWN at 7-years continues to offer an enticing PFS plateau with lorlatinib use in advanced ALK rearrangement+ NSCLC The Learning Oncology Companion from KelleyCPharmD: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Send us Fan MailS4E4 The Oncology Journal Club Podcast In this special ASCO 2026 edition of The Oncology Journal Club, Craig Underhill, Chris Jackson and Kate Clarke unpack some of the meeting's most talked-about studies and discuss what they could mean for clinical practice.From the PROTEUS trial in high-risk prostate cancer and promising advances in RET fusion-positive lung cancer, to a rare sarcoma study demonstrating the potential of CDK4 inhibition, the team explores the data behind the headlines and highlights the challenges of translating trial results into real-world care.The episode also dives into what many are calling the breakthrough study of the meeting – the RESOLUTE-302 trial of daraxonrasib in previously treated pancreatic cancer. With a striking overall survival benefit in a disease that has seen few meaningful advances, the results sparked excitement throughout the oncology community.Along the way, the panel reflects on the atmosphere at ASCO, emerging trends in precision oncology, and how new therapeutic approaches such as KRAS inhibitors, bispecific antibodies and antibody-drug conjugates are reshaping the future of cancer treatment.The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology NetworkVisit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!

Recorded in Chicago, Dr. Aly-Khan Lalani and Dr. Chris Wallis unpack a massive slate of prostate cancer data, fresh from the 2026 ASCO Annual Meeting. The conversation spans the entire disease spectrum, beginning with a deep dive into the PROTEUS trial. Shifting to advanced disease, Dr. Lalani and Dr. Wallis discuss the TALAPRO-3 and the A-DREAM/Alliance A032101 trials. Concluding with a review of sequencing chemotherapy and radioligand therapy in the PLUDO trial, this episode provides an excellent overview of the prostate cancer landscape presented at ASCO 2026.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development. At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneering PD-1xVEGF bispecific antibody, demonstrated a 34% reduction in death risk when combined with chemotherapy for first-line lung cancer treatment. This marks a pivotal moment in cancer therapeutics, illustrating how bispecific antibodies can enhance treatment efficacy. The evolving landscape of cancer treatment continues to highlight the importance of these innovative approaches. Johnson & Johnson's Erleada has shown promising results in prostate cancer, achieving positive outcomes in its Phase 3 Proteus study. The trial emphasized the efficacy of Erleada when administered perioperatively to prostate cancer patients, indicating a shift towards more personalized and comprehensive care that incorporates targeted therapies before and after surgery. In another significant breakthrough, Lilly's Retemvo exhibited dramatic results in early-stage lung cancer with RET fusion-positive markers, reducing disease progression or death by 83% as adjuvant therapy. This underscores the critical role of molecularly targeted therapies for patients with specific genetic profiles, offering hope for improved survival outcomes. On the frontlines of infectious diseases, Shionogi's COVID-19 antiviral Xocova has received FDA approval as a post-exposure prophylactic. This milestone highlights the challenging yet dynamic landscape of antiviral drug development, offering a new tool in managing COVID-19 exposures after previous challenges in demonstrating effectiveness as a treatment. MannKind's inhaled insulin, Afrezza, has been approved for pediatric use. This approval could rejuvenate its market presence by providing a more convenient insulin delivery system aimed at improving adherence and glycemic control among younger patients. In oncology news, Pfizer's Talzenna combination therapy received broader FDA approval for castration-sensitive prostate cancer. This positions it as a competitive option against Johnson & Johnson's PARP inhibitor combination therapy. Additionally, AstraZeneca's Imfinzi and Imjudo combination showed promise in early-stage liver cancer by reducing disease progression risks by 30%, broadening immunotherapy applications. The market dynamics are also shifting with significant strategic movements like Eli Lilly's acquisition of Kelonia Therapeutics for $3.2 billion. This decision is driven by promising in vivo CAR-T data demonstrating unprecedented response rates and reflects the increasing importance of innovative CAR-T therapies in oncology. Eli Lilly's Kelonia Therapeutics' cell therapy showcased an impressive 100% response rate in a Phase 1 trial for relapsed or refractory multiple myeloma. This CAR-T therapy targets the BCMA antigen and could revolutionize treatment paradigms by offering more effective responses. Meanwhile, Pfizer's transformative research on RAS inhibitors holds potential to redefine treatment paradigms in pancreatic cancer—a notoriously difficult-to-treat type due to its complex biology. Revolution Medicines aims to maintain its leadership within this space amidst growing competition. Revolution Medicines also reported compelling results with their KRAS inhibitor, which nearly doubles survival rates for metastatic pancreatic cancer patients harboring KRAS mutations. Given the historically poor prognosis associated with pancreatic cancer, these findings represent a significant advancement in managing this aggressive type. In ovarian cancer research, Gilead's TUB-040 demonstrated a 61% tumor response rate for platinum-resistant ovarian cancer in a Phase 1 trial. This highlights the potential of antibody-drug conjugates (ADCs) to overcome resistance mechanisms and improve outcomes in difficult-to-treat cancers. Regulatory updates include Johnson & Johnson receiving FDA label expansion for Tremfya to inhibit structural joint damage in active psoriatic arthritis patients. This expansion provides broader treatment options for patients suffering from debilitating conditions by reinforcing the role of IL-23 inhibitors in autoimmune disease management. Strategic partnerships are also shaping drug development's future landscape. Notably, Servier's acquisition of Edgewise Therapeutics' muscular dystrophy unit underscores growing focus on rare diseases and neuromuscular disorders. Eli Lilly's agreements with Haisco Pharmaceutical and Hanmi Pharm reflect ongoing R&D investments aimed at expanding therapeutic portfolios across various indications. These developments illustrate a broader trend toward personalized medicine and targeted therapies that enhance treatment efficacy by leveraging specific genetic or molecular characteristics. Despite advancements, challenges remain as exemplified by Oculis' OCS-01 failing Phase 3 trials for diabetic macular edema—highlighting inherent risks in drug development. Overall, these updates underscore significant scientific progress and promise improvements in patient outcomes through novel therapeutic approaches and collaborative efforts within this vibrant industry landscape.Support the show

En este tercer RECAP de la Reunión Anual de la Sociedad Americana de Oncología Clínica, el Dr. Fabián Martínez conversa con el Dr. Salvador Víctor, oncólogo médico titular de la clínica de tumores urológicos del Hospital General de México y médico adscrito al Instituto Nacional de Perinatología. La sesión inicia con el abordaje del cáncer de próstata metastásico sensible a la castración a través del estudio TALAPRO-3, el cual propone la adición de un inhibidor de PARP (talazoparib) al esquema de enzalutamida y terapia de deprivación androgénica (TDA) en pacientes con alteraciones en genes de reparación de la recombinación homóloga (como ATM o CHEK2). Asimismo, en el escenario de la enfermedad localizada de alto riesgo, se evalúan los resultados del estudio PROTEUS. En este punto, se cuestiona el posicionamiento de la neoadyuvancia sistémica con apalutamida más TDA frente a la TDA aislada, considerando que el estándar actual no contempla el tratamiento neoadyuvante y que no existió una comparación directa con la radioterapia definitiva.Posteriormente, la conversación se extiende hacia el ensayo EMERALD-3 en hepatocarcinoma irresecable. Se analiza el rendimiento de combinar inmunoterapia (esquema STRIDE) y lenvatinib con quimioembolización transarterial (TACE) frente a la TACE sola. En el área de tejidos blandos, se evalúa el diseño metodológico del estudio fase III SARC-041 en liposarcoma desdiferenciado; los expertos debaten las implicaciones éticas y prácticas de emplear un brazo de control con placebo frente a abemaciclib, a pesar del impacto significativo que demostró este fármaco en la supervivencia libre de progresión. Finalmente, se revisa el estudio fase IIb TRITON en cáncer de pulmón de células no pequeñas avanzado sin alteraciones conductoras clásicas, evaluando cómo la intensificación del tratamiento con doble inmunoterapia y quimioterapia podría revertir la resistencia intrínseca en poblaciones con co-mutaciones en KRAS, STK11 y KEAP1, caracterizadas por un pronóstico adverso.Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.

Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.

Breaking News podcast just after the long-awaited PROTEUS trial reads out at the ASCO Plenary in Chicago! Plus a simultaneous NEJM paper! Huge day for prostate cancer surgery. Declan and Renu are joined by lead author Dr Mary-Ellen Taplin (Dana Farber Cancer Institute & Harvard University), to tell us about her decades long journey to this huge moment today. PROTEUS is a huge (2,100 men) phase III RCT of men undergoing radical prostatectomy for high-risk prostate cancer, randomised to receive peri-operative ADT + placebo, or ADT plus apalutamide. Mary-Ellen talks to us about the top-line results, and we consider whether this is truly a practice-changing study. Declan also had the honour of being the Discussant at teh ASCO Plenary so he is well placed to give his opinion. Your usual hosts are Declan Murphy & Renu Eapen. Even better on our YouTube channel This is a Themed Podcast supported by our Gold Partner, Johnson & Johnson.Links:PROTEUS NEJM paper

AI. You may have noticed it's everywhere now — in your phone, your fridge, the suspiciously enthusiastic email your boss "wrote" last Tuesday. And cinema, bless its little reactive heart, has been trying to warn us about this for fifty years. The problem is we keep not listening, partly because the warnings have so often arrived in the shape of a sexy lady robot, which is its own diagnosis of the problem.This week, Pete is joined by Chelsea Stardust and Tommy Metz III for a triptych spanning five decades of artificial intelligence horror: Demon Seed (1977), Cam (2018), and Companion (2025). Three films, one increasingly nervous question: what exactly are we asking of AI, and what does it keep becoming anyway?The conversation runs the lineage of synthetic women in cinema — a trope factory that stretches from Metropolis through The Stepford Wives, Blade Runner, Weird Science, Her, Ex Machina, M3GAN, and Subservience, with a foundational-film round that lands on WarGames and 2001: A Space Odyssey. Along the way: the paperclip maximizer as a way of understanding what Proteus actually is, the cultural weight of releasing a forced-pregnancy AI horror four years after Roe v. Wade, platform terms-of-use as the modern book of the vampire, and the genuinely surprising argument that the most hopeful film in the set is the one where a robot drives off into the sunset with all the money.There are detours, because of course there are: villain-era Jack Quaid, Lukas Gage doing the robot, Sophie Thatcher sliding her own intelligence to one hundred percent, and Tommy's new and frankly concerning bedtime ritual.The films:Demon Seed (1977), dir. Donald Cammell, adapted from the Dean Koontz novel, starring Julie ChristieCam (2018), dir. Daniel Goldhaber, written by Isa Mazzei, starring Madeline BrewerCompanion (2025), dir. Drew Hancock, produced by Zach CreggerAlso referenced: Colossus: The Forbin Project, Westworld (1973), Rosemary's Baby, The Omen, Get Out, Promising Young Woman, The Invitation, Assassination Nation, Barbarian. (00:00) - Welcome to Sitting in the Dark (01:29) - The AI Experience (04:26) - Foundational AI Films (05:42) - Demon Seed (25:55) - Cam (42:16) - Companion (01:04:46) - Coming Attractions ... TBA! Support The Next Reel Family of Film Shows:Become a member for just $5/month or $55/yearJoin our Discord community of movie loversThe Next Reel Family of Film Shows:Cinema Scope: Bridging Genres, Subgenres, and MovementsThe Film BoardMovies We LikeThe Next ReelSitting in the DarkConnect With Us:Main Site: WebMovie Platforms: Letterboxd | FlickchartSocial Media: Facebook | Instagram | Threads | Bluesky | YouTube | PinterestYour Hosts: Chelsea | Kyle | Kynan | Pete | Tommy Shop & Stream:Merch Store: Apparel, stickers, mugs & moreWatch Page: Buy/rent films we've discussed

GC13 and David discuss Sasha’s Angels and Ulm Town Road from Amphibia. Two episode titles, two references—it was a good day. The spotlight gets to shine in new places, with Sasha’s eponymous Angels getting one episode and the Ulms in another, showcasing their beautiful (and stupid) home city. Unfortunately as beautiful as Proteus is, there might not have been enough episode to show it off to us in all of its glory. Such is fate.

Today Griffey and Dandino blur the line between man and machine in Demon Seed. They discuss the films blend of technological and exploitative horror, the focus on man as the evil ghost in the machine, and Proteus's insane plan for the future of his AI mega brain. This movie rises above the explotative, trashy concept to become a real Messed Up thinker.  Synopsis: A scientist creates Proteus--an organic super computer with artificial intelligence which becomes obsessed with human beings, and in particular the creator's wife. Starring: Julie Christie, Fritz Weaver, Gerrit Graham Directed by Donald Cammell Youtube: https://youtu.be/CM6Fb4VibJ0 Help us make our first feature length Messed Up Movie:  https://www.indiegogo.com/projects/mr-creamjean-s-hidey-hole-horror-comedy-movie#/  Support the show on the Patreon: https://www.patreon.com/c/messedupmoviespod  

Avez-vous déjà essayé de prendre la posture de Superman, avant un entretien d'embauche par exemple, pour vous sentir plus confiant ? Si c'est le cas, vous avez utilisé sans le savoir l'effet Proteus. C'est le fait de se mettre dans la peau d'une autre personne, d'un avatar, pour lui emprunter certains traits. Des chercheurs de l'Université des Arts et Métiers de Laval et le centre Inria de l'Université de Rennes ont demandé en 2023 à des cobayes de se mettre dans la peau de Léonard de Vinci pour se plier à des exercices de créativité. Résultats : les sujets qui se prennent pour Léonard de Vinci ont eu 47% plus d'idées que ceux qui ne le font pas. Comment utiliser l'effet Proteus ? Pourquoi est-ce utile ? Quelles sont ses applications avec la réalité virtuelle ? Écoutez la suite de cet épisode de "Maintenant Vous Savez ". Un podcast Bababam Originals, écrit et réalisé par Maëlle Diallo. Première diffusion : novembre 2023 À écouter aussi : ⁠⁠Qu'est-ce que la French Touch ?⁠⁠ ⁠⁠Comment éloigner les guêpes ?⁠⁠ ⁠⁠Qu'est-ce que le phénomène du pénis d'été?⁠⁠ Retrouvez tous les épisodes de ⁠⁠⁠"Maintenant vous savez".⁠⁠⁠ Suivez Bababam sur ⁠⁠⁠Instagram⁠⁠⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

Recorded live at MJBizCon 2025, host Mary Jane Gibson sits down with Dawne Morris, CEO of Proteus 420, to talk about building privacy-first cannabis tech that helps operators compete smarter. From early compliance challenges to the launch of Phoebe AI, this conversation explores how secure, business-owned data can support better pricing, stronger retail performance, and more trustworthy cannabis operations. Sponsored by SHOPLINE in association with ICBC.WEBSITE: https://cannatechtoday.com/Make sure to follow our other social media platforms to stay up-to-date on all things Cannabis & Tech Today.https://twitter.com/cannatechtodayhttps://www.facebook.com/CannaTechTodayhttps://www.instagram.com/cannatechtoday

Dans la Bible, Lucifer était l'ange préféré de Dieu. Il a été déchu après avoir refusé de s'agenouiller devant l'ultime création de son créateur : l'Homme. Après s'être vu claqué au nez la porte du paradis,  il est devenu le maître de l'enfer. C'est d'après lui que le psychologue Philip Zimbardo a nommé l'effet Lucifer. C'est un processus de transformation à travers lequel une personne parfaitement intégrée en société, et même considérée comme gentille, peut commetre des actes atroces. Pour étudier ceci, Zimbardo a mené une expérience effrayante et aujourd'hui très connue : l'expérience de Stanford. Qu'est-ce que l'expérience de Stanford ? En quoi consiste-t-elle ? Comment Zimbardo explique-t-il ces résultats ? Écoutez la suite de cet épisode de "Maintenant vous savez". Un podcast Bababam Originals, écrit et réalisé par Antonella Francini Première diffusion : novembre 2022 À écouter aussi : ⁠Qu'est-ce qu'un vampire énergétique ?⁠ ⁠Qu'est-ce que l'effet Proteus ?⁠ ⁠Qu'est-ce que le paradoxe de Fermi ?⁠ Retrouvez tous les épisodes de ⁠"Maintenant vous savez".⁠ Suivez Bababam sur ⁠Instagram⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sei mite, porti gli occhiali e lavori in un ufficio silenzioso. Ma online, indossi un'armatura nera, impugni un'ascia da gigante e spingi gli altri giocatori al centro della strada. Pensi che sia solo un gioco? La verità è più inquietante. Non sei tu che controlli l'avatar. È l'avatar che sta controllando te.In questo episodio di Psicologia Cognitiva Applicata, entriamo nel territorio profondo e scivoloso dell'Identità Digitale. Esploriamo il fenomeno psicologico che prende il nome dal dio greco mutaforma: l'Effetto Proteus.

Jeudi 25 septembre, l'armée de terre française a présenté ses objectifs pour les mois et années à venir. À la lumière des combats en Ukraine, elle se prépare à un champ de bataille plus contesté, plus étendu et plus transparent, où robots et drones seront omniprésents. Rediffusion du 28 septembre 2025. Pierre Schill, chef d'état-major de l'armée de Terre s'appuie sur les chiffres : chaque jour, sur le front ukrainien, 1 500 soldats russes sont mis hors de combat, dit-il. Une attrition vertigineuse qui ne serait pas supportable pour l'armée française. Sur le champ de bataille, les machines seront donc bientôt dédiées à subir les chocs les plus rudes, analyse le général Bruno Baratz en charge du commandement du combat futur.  « Le champ de bataille de demain ressemble curieusement à celui d'aujourd'hui, mais avec plus de robotisation et de "dronisation". L'augmentation de la transparence du champ de bataille, rendue possible par la multiplication des capteurs spatiaux, acoustiques, terrestres et avec l'exploitation de ces données par l'intelligence artificielle, crée une forme de transparence du champ de bataille, explique-t-il. On voit bien que c'est un univers qui est devenu très hostile pour la présence des soldats et des êtres humains, et qu'on arrive à compenser cela aujourd'hui par plus de robots, ce qui amènera un peu de masse et surtout protègera beaucoup plus nos hommes ». Deux capacités ont été rapidement développées pour durcir les forces : le canon antidrones Proteus et le Mepac, un mortier embarqué et non plus tracté, qui démultiplie la puissance de feu des unités d'infanterie, précise le général Schill : « S'agissant des Mepac, c'est-à-dire ce mortier de 120 mm embarqué à bord d'un Griffon [véhicule blindé médian - NDLR], nous en avons commandé 54. Les premiers arrivent. Ils ont été déployés au sein du troisième régiment d'artillerie de marine à Canjuers. Mon objectif est que tout début 2026, je sois en mesure de déployer en opération une première unité avec ces mortiers. S'agissant du Proteus, c'est-à-dire ce canon de 20 mm auquel nous avons adjoint une couche d'intelligence artificielle de façon à pouvoir lutter contre les drones, les premiers sont déjà déployés dans l'armée de terre, au sein notamment du 35ème régiment d'artillerie parachutiste de Tarbes. On va monter l'an prochain à un volume d'une cinquantaine de canons. Ils peuvent être déployés en opération dès aujourd'hui, si c'était nécessaire ». À lire aussiAu Salon des forces spéciales, les drones militaires s'imposent pour tous types de missions « Il faudrait 77 000 opérateurs de drones » La robotique terrestre fait son apparition : Pandragon, une première unité, composée de 20 robots d'abord utilisés pour les taches logistiques, sera opérationnelle à l'été 2026. Un escadron de drones va également voir le jour. La doctrine d'emploi s'écrit maintenant, les drones d'attaque vont venir compléter la traditionnelle artillerie et donner de l'allonge aux troupes au sol, insiste Bruno Baratz : « L'objectif pour nous, c'est d'éviter que l'ennemi se concentre sur la zone de front et donc d'être en mesure de le frapper le plus loin possible et d'éviter justement les concentrations de force à proximité de nos brigades, de façon à leur faciliter la manœuvre. La tendance générale, c'est bien le développement de ces feux dans la profondeur, même pour une unité d'infanterie qui ira tirer au-delà des vues directes. On voit arriver les munitions téléopérées, ces drones qui sont capables d'amener des charges à différentes distances et qui vont venir compléter finalement le travail de l'artillerie. » Il faut désormais des soldats, à la fois plus durcis et plus innovants, martèle le chef d'état-major de l'armée de Terre, le général Pierre Schill : « Nous devons recruter une partie de nos soldats ou de nos cadres dans ces nouvelles techniques, de manière à avoir des soldats pour le brouillage, pour l'emploi des drones, pour l'emploi des communications. La montée en technique de l'armée de terre est une réalité. J'ai 77 000 soldats dans la force opérationnelle terrestre, donc il me faudrait 77 000 opérateurs de drones, chacun dans son domaine. » L'armée de terre vit une révolution, avec l'usage illimité des drones et de la robotique, elle est en passe de devenir une armée de combattants techniciens. À lire aussiLes robots sur le champ de bataille

Episode SummaryWhy do we play the video games that we play? Is interest in the strategy game genre truly waning globally over time? Greg and Lewis sit down with gaming psychology pioneer and Quantic Foundry co-founder Nick Yee to answer these and many other questions. From dissecting the Proteus effect to comparing and contrasting the psychological motivations that drive GTA Online, Fortnite, and Europa Universalis players, Dr. Yee takes us on a whirlwind tour of his company's Gamer Motivation Model that contains insights from >1.75 million gamers.What You'll LearnThe Proteus effect: How inhabiting an attractive or tall avatar can impact your real-world confidence level and negotiating tactics.The Strategy genre slump: Why interest in strategic thinking has dropped from the 50th to the 33rd percentile since 2015 in Quantic Foundry's gamer database, and how it appears to be linked to a global drop in conscientiousness (one of the "Big Five" personality traits).Gamer motivation models: What are some of Quantic Foundry's 12 psychological traits that drive video game play (i.e., Destruction, Power, Community, Strategy, Completion, Excitement) and how is this framework used to answer different questions than SDT (Self-Determination Theory).Industry Insights: How studios psychologically segment players to help guide their future content roadmaps, drive UA, and more.The RPG accident: Why the RPG genre is actually a bundle of two different player types.Episode Timestamps01:45 – The "wildly optimistic" era of mid-2000s MMOs .02:35 – VR Lab Experiments: Putting people in bodies that aren't their own .05:30 – Does the "virtual" you linger after you log off? .08:50 – The 12-Factor Gamer Motivation Model explained .11:50 – The "Bummer" Stat: The steady decline of strategy games .14:50 – Is Social Media or AI "shortening" our collective attention span? .18:50 – Why Balatro succeeds in a world that hates long-term planning .21:10 – Quantic Foundry vs. Self-Determination Theory (SDT) .32:10 – The hidden psychology of Idle Clicker games .35:45 – Breaking down the player profiles of GTA Online vs. Fortnite .Resources MentionedQuantic Foundry: quanticfoundry.comGamer Motivation Profile: Take the 5-minute survey here .Games Discussed: World of Warcraft, Civilization VI, Europa Universalis V, Balatro, GTA V, and Fortnite.Connect with our Guest:Nick Yee: LinkedInCall to ActionDiscover your "Gaming Posse": Take the Gamer Motivation Profile to see which of the 2 million surveyed gamers share your psychological DNA and get custom game recommendations.Join the Player Driven Discord: https://discord.gg/kPS6yPrB

Send a textMike Romance has spent nearly two decades operating at the intersection of manufacturing engineering, automation, validation, and operations leadership within the life-sciences ecosystem. His career spans startups and established organizations alike, with hands-on experience taking products from early development through GMP-ready, high-volume production. Across roles in process development, automation, quality systems, and manufacturing strategy, Mike has built a reputation for combining technical rigor with pragmatic execution.Most recently at Quantum-Si, Mike played a central role in scaling operations to support the commercialization of the Platinum protein sequencing platform while laying the groundwork for next-generation technologies like the Proteus platform. Working within a lean and highly agile leadership team, he helped establish scalable manufacturing foundations spanning CM-managed instrument supply, internal reagent kit production, and advanced silicon-based consumables—while navigating the realities of fast-moving product roadmaps and constrained resources.Earlier in his career, Mike held engineering and leadership roles at organizations including Illumina, Dexcom, GenMark Diagnostics, Truvian, and Encodia. Along the way, he's led pilot-line development, automation strategy, equipment qualification, validation programs, and process controls—often in environments where the path forward wasn't clearly defined.What sets Mike apart is not just his command of acronyms—GAMP, CQV, QbD, DFSS, FMEA—but his philosophy that systems only work when people do. He actively practices emotionally intelligent leadership, prioritizing trust, clarity, and psychological safety while still holding teams to high technical and operational standards. As Mike explores his next chapter, this conversation focuses on the lessons he's learned building resilient manufacturing systems—and the kind of organizations where he believes he can make the biggest impact next.LINKS:Guest LinkedIn: https://www.linkedin.com/in/mikeromance/Aaron Moncur, host The Wave is  a place for engineers to actively learn, share ideas, and engage with people doing similar work. Learn more at thewave.engineer Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us Watch the show on YouTube: www.youtube.com/@TeamPipelineus

Send me a question or story!In veterinary dermatology, gram-negative rods like Pseudomonas, E. coli, Proteus, etc. can develop in chronic or deep skin infections. When systemic therapy is needed, culture and sensitivity are essential. But what are some of the more common antibiotics that are effective against these nasty bugs?Common options include fluoroquinolones, potentiated penicillins, later-generation cephalosporins, etc. These organisms are frequently multidrug-resistant so appropriate diagnostics and re-evaluation is crucial.Learn more as we continue our current series on DERM DRUGS on this week's podcast!00:00 – Intro01:36 – General Things to Keep in Mind03:49 – The Importance of Topical Therapy05:31 – Systemic Therapy Options06:38 – Antibiotic Choices10:35 – Last Resort Antibiotics12:44 – Overview13:39 – Outro

Send a textOver the past few years, artificial intelligence has rapidly entered drug discovery — but one of the true “holy grail” challenges inside pharma is no longer just predicting what proteins look like, but understanding how molecules actually interact: how proteins bind drugs, antibodies, RNA, and each other, and how those insights can guide better decisions long before anything reaches the lab.Early breakthroughs in structure prediction made protein models widely accessible, but real biology happens at interfaces, in motion, and often in fleeting conformations that determine whether a therapy ultimately succeeds or fails. Today's conversation explores what it means to move into this next chapter — where structural predictions are translated into actionable insight for real-world drug development.Joining us are two scientists from Merck KGaA, Darmstadt, Germany ( https://www.emdgroup.com/en ), working at the intersection of protein structure prediction, molecular dynamics, and generative design, helping to build internal platforms that turn computational models into practical decision tools for therapeutic discovery.Dr. Stephanie Linker, Ph.D. is a Senior Computational Biochemist in Merck's Group Digital Innovation unit, where she leads initiatives in generative antibody design, de novo protein binder development, and advanced structure prediction platforms. Her work focuses on how molecular shape, flexibility, and dynamics influence whether a designed molecule actually performs in biological systems.Dr. Philipp Schnee, Ph.D. is a Computational Protein Design expert at Merck KGaA, currently part of the GoGlobal Data & AI rotation program. His research bridges high-resolution molecular dynamics simulations with experimental biochemistry to understand protein function, mutation effects, and mechanisms that can be leveraged for enzyme engineering and inhibitor design.Together, their work reflects a broader shift happening across the pharmaceutical industry — away from static structures and standalone models, and toward integrated platforms that combine folding, binding, ranking, and experimental validation to guide smarter, faster therapeutic decisions.In this episode, we explore what these next-generation tools can do today, where their limitations remain, and why the ability to move from structure prediction to decision-ready insight may become one of the most important frontiers in modern drug discovery.AI drug discovery, protein structure prediction, computational biology, biologics design, pharmaceutical R&D#DrugDiscovery #ArtificialIntelligence #AlphaFold #ProteinFolding#Biotech #PharmaInnovation #ComputationalBiology #StructuralBiology #AIinHealthcare #AntibodyEngineering #MolecularDynamics #FutureOfMedicine #SystemsBiology #LifeSciences #ProgressPotentialPossibilities #MachineLearning #BioTechPodcastSupport the show

On his episode of That Tech Pod, Kevin and Laura sit down with Ray Biederman, CEO and Co-Founder of Proteus Discovery Group, to talk about what actually happens when legal theory, technology, and human behavior collide. Ray walks through his unusual path from music education to law to legal tech, and how that background shaped the way he thinks about systems, judgment, and risk. Rather than chasing hype, he explains why Proteus focuses on defensible outcomes and practical decision-making in a crowded eDiscovery market.The conversation gets into lessons Ray has learned by wearing every hat, product builder, services leader, and still-practicing attorney. He shares what courtroom experience teaches that product teams often miss until something breaks, especially around context, intent, and how small mistakes compound once data starts moving. Ray also offers a measured take on AI-driven review, warning against the industry's tendency to overcorrect by trying to remove human judgment entirely, and highlights the ethical tensions that surface when AI reveals patterns no one anticipated. The episode closes with a forward-looking discussion on deepfake evidence, verification challenges, and the growing risk posed by data traveling across too many systems without enough accountability. Ray Biederman, Chief Executive Officer and Co-Founder of Proteus Discovery Group, LLC, has worked in every phase of electronic discovery for more than two decades. He is a Super Lawyer in the area of eDiscovery, has been cited in multiple court opinions as an expert witness, and is adjunct faculty for eDiscovery at the IUPUI School of Informatics and Computing. He consults on Information Governance policies and procedures related to cybersecurity and its intersection with government regulation and industry-specific best practices. Outside of his eDiscovery experience, Ray is an active litigator representing clients in product liability work, business valuation disputes, and contract disputes. He is also a founding partner in Mattingly Burke Cohen & Biederman. He was previously an associate at Barnes & Thornburg, LLP. He holds a B.M. in Music Education from Butler University and a J.D from Indiana University, the Robert H. McKinney School of Law.

Greeetings!Welcome to a new month of UCP fun as we dive back into a show that is one of our favourites, Good Game. We revisit Bajo and Hex, as they battle Hex's sugar zoomies, and Bajo's urge to find a game that is the perfect level of discovery, gameplay and storyline (SPOILERS: Nothing meets Goldie Locks needs).The episode consists of arty explorer Proteus, epic JRPG Persona 4 Golden and FPS Crysis 3. As well as Goose taking Cliff and Ash to school to teach them what a Reboot is... Cliff Rant Incoming!Watch Good Game here: https://youtu.be/eYLyPy2cmPw?si=m2nh67db89zdIJDPDON'T FORGET TO VOTE IN THE FLOPPIES: https://forms.gle/LF4aYLozHfScLDdu6Theme song by Other ChrisFollow Under Consoletation on BlueSkyFollow Under Consoletation on TwitterFollow Under Consoletation on InstagramSend your thoughts to feedback@underconsoletation.com Hosted on Acast. See acast.com/privacy for more information.

En este episodio de Quiero Ser Podcaster PRO charlo con Luis Alberto Martín (@lamartinvoz) para ponernos al día de todos sus proyectos recientes en el mundo del audio.Hablamos de su papel en la nueva ficción sonora Dark Atlas Sumbra, creada como parte del universo del videojuego Dark Atlas Inferno, y escuchamos fragmentos del podcast para entender cómo funciona un proyecto transmedia. Comentamos también su participación en La cumbre de los horrores (Podium Podcast) y su trabajo en Proteus, una serie que mezcla divulgación científica y narrativa sonora.Además, nos cuenta su aventura adaptando contenido para el canal de YouTube YesLucid, donde dobla vídeos sobre Minecraft con un estilo muy dinámico. A partir de ahí, abrimos debate sobre formatos, vídeo podcast, canales de reacción y el papel de la IA en la creación de contenidos.Un episodio variado y lleno de cortes de audio, perfecto para explorar la diversidad de formatos que puede tener un creador de voz.__Mis servicios, libro, edición y consultorías en www.quieroserpodcaster.com Hosted on Acast. See acast.com/privacy for more information.

Two episodes with serious problems. Dan had to watch the 2nd one twice to try to make sense of it!

Plongez avec Aurélien et Marc au cœur de la révolution électrique avec une histoire à la fois méconnue et fascinante, celle de Charles Proteus Steinmetz, ce petit homme à la silhouette fragile qui a électrisé l'Amérique de la fin du XIXe siècle et dont le génie a donné naissance au monde moderne.Vous souhaitez comprendre pourquoi, chaque fois que la lumière s'allume chez vous, un peu de l'esprit de Steinmetz brille ? Laissez-vous porter par cet épisode, faites connaissance avec celui qui a écrit les grandes lois de l'électricité et permis à des nations entières de s'éclairer.

In this Micro Minutes episode, Luis breaks down classic microbiology traits that usually hold true, but not always.  From indole-negative E. coli to non-swarming Proteus and oxidase-negative Pseudomonas, this quick episode highlights real-world exceptions that can catch techs and students off guard. Learn how to spot: Indole-negative E. coli (98% rule + inactive biotypes) Lactose-fermenting look-alikes like Citrobacter freundii Proteus species that don't swarm Pseudomonas species that test oxidase negative A fast, practical reminder that no single biochemical test should stand alone.   Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi  

Over the past two decades, no company has done more to shape the American workplace than Amazon. In its ascent to become the nation's second-largest employer, it has developed an aggressive corporate culture and pioneered using technology to hire, monitor and manage workers.Now, interviews and a cache of internal strategy documents reveal that Amazon executives believe their company is on the cusp of their next big workplace shift: replacing more than half a million jobs with robots.Karen Weise takes us inside Amazon's push toward automation and the implications for the company and potentially for the broader economy.Guest: Karen Weise, a technology correspondent for The New York Times, based in Seattle.Background reading: Amazon plans to replace more than half a million jobs with robots.Meet Sparrow, Cardinal and Proteus, the robots powering Amazon's automation.Photo: Emily Kask for The New York TimesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

Where would this show be without forgotten Thing ripoffs boasting 3 minutes of Doug Bradley in full head makeup choking on tentacles that look like humongous earthworms? In honor (we guess) of its 30-year anniversary, the boys were once again talked into discussing a movie none of them had seen before by friend of the show/past guest Benji, the one and only PROTEUS (1995)! Based on the book SLIMER by Harry Adam Knight, the film version borrows as much from Raimi as it does Carpenter, to varying degrees of success. It's all worth it for the last 15 minutes of absolute ridiculousness. Come on, we're investigating this creepy abandoned oil rig with our fanny pack full of drugs - what could go wrong? Learn more about your ad choices. Visit megaphone.fm/adchoices

paypal.me/LibroTobias ko-fi.com/asier24969 Continuamos el recorrido por la filmografía de David Lynch con su segunda película. En 1980 y con Mel Brooks como productor no acreditado, Lynch estrenaba “El hombre elefante”. Con algunos cambios, el maestro de Montana adaptaba la historia real de Joseph Merrick, el primer caso diagnosticado de Síndrome de Proteus. Presentación, dirección, edición y montaje: Asier Menéndez Marín Diseño logo Podcast: albacanodesigns (Alba Cano) Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Avez-vous déjà essayé de prendre la posture de Superman, avant un entretien d'embauche par exemple, pour vous sentir plus confiant ? Si c'est le cas, vous avez utilisé sans le savoir l'effet Proteus. C'est le fait de se mettre dans la peau d'une autre personne, d'un avatar, pour lui emprunter certains traits. Des chercheurs de l'Université des Arts et Métiers de Laval et le centre Inria de l'Université de Rennes ont demandé en 2023 à des cobayes de se mettre dans la peau de Léonard de Vinci pour se plier à des exercices de créativité. Résultats : les sujets qui se prennent pour Léonard de Vinci ont eu 47% plus d'idées que ceux qui ne le font pas. Comment utiliser l'effet Proteus ? Pourquoi est-ce utile ? Quelles sont ses applications avec la réalité virtuelle ? Écoutez la suite de cet épisode de "Maintenant Vous Savez ". Un podcast Bababam Originals, écrit et réalisé par Maëlle Diallo. Première diffusion : 29 novembre 2023 À écouter aussi : Qu'est-ce que la French Touch ? Comment éloigner les guêpes ? Qu'est-ce que le phénomène du pénis d'été? Retrouvez tous les épisodes de ⁠"Maintenant vous savez".⁠ Suivez Bababam sur ⁠Instagram⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, I sit down with Erika Andersen, bestselling author and founder of Proteus, a coaching and consulting firm focused on leader readiness. Now in her seventies, Erika has turned her lifelong wisdom toward one of life's biggest opportunities: how to age with strength, purpose, and joy. Her journey is an inspiring reminder that growth and vitality don't have an expiration date.Some Key Highlights:The 50-year practice that has supported her mental and physical healthA powerful way to transform negative self-talk into fuel for resilienceWhy it's never too late to expand your flexibility—physically and mentallyThe principles Erika uses to envision and create a vibrant later lifeHow living in Spain has reshaped her outlook on aging and communityErika's story shows that getting older can be a time of exploration, curiosity, and renewed energy. With warmth and candor, she shares how we can reframe aging, embrace change gracefully, and keep tapping the edges of our potential. This conversation is for anyone who wants to approach the future with curiosity, confidence, and a fresh sense of possibility.Erika's LinksWebsite: https://erikaandersen.com/Books: https://erikaandersen.com/books/LinkedIn: https://www.linkedin.com/in/andersenerika/We'd appreciate a review on Apple Podcasts and/or Spotify. Connect with John Geraghty at:Website: https://john-geraghty.com/LinkedIn: https://www.linkedin.com/in/john-geraghtyInstagram: https://www.instagram.com/coachjohngeraghty/ Facebook: https://www.facebook.com/coachjohngeraghty/YouTube: https://www.youtube.com/@John-GeraghtyLearn about The Flow Cultivator program: https://theflowcultivator.com/Grab a copy of The Prism of Perspective Book here: https://a.co/d/f5Lfqbn

Neste episódio da série de doenças ortopédicas raras, Zaira Pinto, médica ortopedista e conteudista do Portal Afya, explora desde os aspectos genéticos e clínicos até os tratamentos mais recentes da síndrome de Proteus, incluindo terapias inovadoras que estão mudando o panorama do manejo dessa síndrome. Ouça agora!

That slippery Proteus and breakfast for beasts.

Most golfers and baseball players chase speed and distance… but ignore the root cause of why they're stuck. In this episode of The Undercurrent, Dr. Jared Bickle breaks down how to assess, treat, and train the rotational athlete with a precise framework that bridges rehab and elite performance. We cover: How the golf swing is more physically demanding than most people realize, and using the TPI (Titleist Performance Institute) framework for assessing and treating the numerous golf injuries that exist Why trail-side low back pain is the most common injury in golfers, and the connection to hip and thoracic mobility  How to use technology like the Neubie and Proteus for faster recovery and bigger performance gains with rotational athletes The hidden “drivers” behind swing mechanics, pain, and performance – and why speed and power do not always translate to a better swing Building speed and power the right way, without sacrificing durability If you treat or train rotational athletes – or if you are one yourself – this episode is for you. You'll walk away with practical insights that shift how you view the body and the ways you can unlock greater performance and longevity.  

This week Kelley and Jordan go over, "Sinbad: Legend of the Seven Seas." In this episode they catch you up on the past three weeks, talk about their love for Coke Zero, they believe that Proteus is in love with Sinbad, and are not feeling this love triangle.Use our special link https://zen.ai/0LmmcoxSI8fB_4ix3nioEncL0–7XVkMKbLJizxRQqXv4 to save 30% off your first month of any Zencastr paid plan.Ready to shop better hydration, use our special link https://zen.ai/0LmmcoxSI8fB_4ix3nioEr1GvXnsPkWemdSR5s0AtUc to save 20% off anything you order.Listen to us on Apple Podcast, Spotify, or anywhere else you listen to podcastsApple Podcast: https://podcasts.apple.com/us/podcast/so-you-think-youre-iconic/id1528462095Spotify: https://open.spotify.com/show/1sV5jnnsnI7mcCk3pA7yVT?si=rD_0rUScQS2y2arFbbJZPg&dl_branch=1Instagram: https://www.instagram.com/sytyipodcast/Twitter:  https://twitter.com/SYTYIPODCASTYoutube: https://www.youtube.com/channel/UClWbWmlH_IEXGy9Dbbeg--A

Send us a textIn today's episode, Paul will explore how he scales hardware teams, builds for manufacturability, navigates supply chain complexity, mentors engineers, and embraces community‑driven innovation. Get ready for insights on leadership, prototyping, and bringing hardware to life from idea to market.Main Topics:Proteus Motion's V1 and V2 machine developmentEngineering career progressionHardware product design and manufacturingConsulting and entrepreneurshipNew York Hardware Meetup community buildingAbout the guest: Paul Vizzio is a seasoned mechanical engineer and hardware leader with a diverse background spanning consumer electronics, cleantech, and defense. Starting as a product management intern at SolidWorks, he later managed undersea vehicle projects at the Naval Undersea Warfare Center. As the first mechanical engineer at goTenna, he developed both consumer and military-spec products from concept to production in under a year.In 2017, he founded Vizeng, providing end-to-end mechanical and supply-chain consulting to NYC hardware startups. He also led product development for RoadPower's regenerative road systems.Since 2019, Paul has led hardware efforts at Proteus Motion, overseeing team growth, R&D, and supply chain. His work includes redesigning the V1 system and launching the V2 within a year—contributing to Proteus's adoption by 400+ pro sports teams and clinics. He also co-organizes the NY Hardware Meetup and founded the D2C pet brand RemieDog, reflecting his passion for innovation and community-building.Links:Paul Vizzio - LinkedInVizeng WebsiteAaron Moncur, hostClick here to learn more about simulation solutions from Simutech Group.

Dutch and Tena review a 1977 film called Demon Seed. The movie's premise is about a Doctor who creates an artificial intelligence program named Proteus. Proteus is sentient and creates its own agenda to infiltrate the human bloodline. It does this by creating synthetic semen and recoding a woman's host's DNA to birth a hybrid baby. In this show, we discuss how this connects to modern A.I. and the experimental pandemic vaccine. Tune in to the discussion. 

Greg Weisman discusses themes of prejudice and the descendants of the Greek gods and monsters while Jamie Thomason talks about casting and directing this episode as we dive into this backdoor pilot for a potential spinoff. Greg Weisman also discusses, in depth, what that spinoff would have entailed, characters that would have participated – including one very familiar to us. We are also joined by producer, writer, and author, Samuel Garza Bernstein who talks about the life and career of Hollywood icon, Roddy McDowall (who voiced Proteus in this episode)… and the biography that he's writing about him. We all... Continue reading

Welcome to Dev Game Club, where this week we continue our series on walking simulators with 2012's Dear Esther, played here in a 2017 "Landmark Edition" but based on a 2007 Source mod for Half-Life 2. We of course set the game in its time, spend a fair amount of time on randomness and meaning, and open the cellar door. Dev Game Club looks at classic video games and plays through them over several episodes, providing commentary. Sections played: The whole shebang Issues covered: walking simulators, 2012 in games, a little history of The Chinese Room (the company), a little digression on The Chinese Room (the thought experiment), influences, developing in the mod community, the role of randomness, discovering the randomness, justifying the randomness, mod communities replaying games, not discussing games as you play them, writers having the same space to play, 30 seconds of depressing poetry, "cellar door," a quality of lovely phonemes, the facts we know and the things we might interpret, a dreamy narrative space, Tim reveals his baseball knowledge, a metaphor for grief and an otherworldly space, rebirth, a car accident setting vs a gurney setting, things you can miss, not a thing video games would do, appreciating a new design space, directors' commentaries, crematory urns, one of the props, the impact of the ultrasound, needing to relate to the characters, the potential for missing things. Games, people, and influences mentioned or discussed: Fez, The Stanley Parable, The Chinese Room, Dishonored, Halo 4, Diablo III, Kingdom Hearts 3D: Dream Drop Distance, Forza Horizon, New Super Mario Bros U, Far Cry 3, XCOM Enemy Unknown, Alan Wake's American Nightware, Hitman Absolution, Assassin's Creed 3, Max Payne 3, Mass Effect 3, Borderlands 2, Darksiders 2, Spec Ops: The Line, Dragon's Dogma, Fez, Journey, The Walking Dead, Hotline Miami, Spelunky, Papo y Yo, Bastion, Super Hexagon, Sumo Digital, Dan Pinchbeck, Jessica Curry, Rob Briscoe, Independent Games Festival, Korsakovia, Amnesia: A Machine for Pigs, Everyone's Gone to the Rapture, Unity, CryEngine, Little Orpheus, Still Wakes the Deep, Vampire: Bloodlines (series), Hardsuit Labs, Brian Mitsoda, John Searle, Alan Turing, William S. Burroughs, Nigel Carrington, Proteus, Halo, Drew Barrymore, Donnie Darko, Rogue Legacy 2, David Lynch, Lost Highway, Inland Empire, Laura Dern, Waiting for Godot, True West, Sam Shepard, Firewatch, LucasArts, 343 Games, Kevin Schmitt, Metal Gear, Death Stranding, Trespasser, Tacoma, Jedi Starfighter, Daron Stinnett, Outer Wilds, Kirk Hamilton, Aaron Evers, Mark Garcia. Next time: The Stanley Parable Twitch: timlongojr  Discord  DevGameClub@gmail.com 

The Naval Research Laboratory's PROTEUS program is a cutting-edge maritime domain awareness system designed to provide near-real-time global maritime situational awareness for agencies and partners. The program integrates multi-source data ingestion and fusion services to identify, query and filter maritime vessels based on user-defined criteria. During Sea-Air-Space 2025, Alan Hope, head of the NRL's mission development branch, spoke to GovCIO Media & Research about how Homeland Security Investigations, the Department of Transportation's Maritime Administration and other agencies are using PROTEUS to fulfill their mission. Hope says that PROTEUS is crucial assist to human analysts at agencies, using AI to sift through vast datasets to highlight potential threats and anomalies, which allows experts to focus on validation and decision-making rather than raw data interpretation. Hope also talks about the PROTEUS user experience, highlighting the cloud-based, easily accessible workbench that provides real-time updates and historical data for in-depth analysis, fostering collaboration among users across different agencies and locations.

Listen to 111 Future Now Show Fortunately, most power has been restored after a blackout brought the Spain and Portugal, and parts of France to a standstill on Monday. Or is it? There seems to have been a silver lining to this massive outage, hiding in plain sight.Can you guess?  A clue would be…candles..another would be …neigbors..Got it?  Meanwhile we work with Grok3’s Ara as a detective sleuth, investigating the who, what, and why’s of this strange case of power gone awry..Historical parallels to past European blackouts are drawn, highlighting the vulnerability of interconnected power systems. While the official cause remains uncertain, geopolitical motives, particularly from Russia, are discussed as a potential, though unproven, driver for such an intentional act to test NATO resilience. Also this week, aging in space and what it means for us, galaxies aimed mysteriously at us around Andromeda, Synthetic leaves for fuel and plastic generation, and other topics such as economic realignments, religious influences on global politics, the potential for advanced technology like space elevators and bioreactors, and the development of micro-robots for brain surgery, along with more abstract concepts like the nature of consciousness and the unity of humanity. Enjoy!  Spain and Portugal power outage:”induced atmospheric vibration”

In a very special edition of the WhatCulture Wrestling Podcast, Michael Hamflett sits down with Simon Miller just days removed from one of the wildest 24 hours of his career. Listen in as the pair go deep...- Candid Thoughts On Losing His PROGRESS Proteus Title To Paul Walter Hauser - How They Put The Match Together - Working A Musical Hours Before Wrestling - What Happens Next?Enjoy!@MichaelHamflett @SimonMiller316 @WhatCultureWWE Hosted on Acast. See acast.com/privacy for more information.

Merriam-Webster's Word of the Day for April 9, 2025 is: vouchsafe • vowch-SAYF • verb Vouchsafe is a formal and old-fashioned word meaning "to give (something) to someone as a promise or a privilege." // He vouchsafed the secret to only a few of his closest allies. See the entry > Examples: "[Arthur] Conan Doyle (1859-1930) wrote several horribly chilling tales of the supernatural, although this might surprise readers who only know his Sherlock Holmes stories. When there are eerie goings-on in the Holmes yarns, a rational explanation is inevitably vouchsafed, à la Scooby-Doo." — Jake Kerridge, The Daily Telegraph (London), 20 Dec. 2023 Did you know? Shakespeare fans are well acquainted with vouchsafe, which in its Middle English form vouchen sauf meant "to grant, consent, or deign." The word, which was borrowed with its present meaning from Anglo-French in the 14th century, pops up fairly frequently in the Bard's work—60 times, to be exact. "Vouchsafe me yet your picture for my love," beseeches Proteus of Silvia in The Two Gentlemen of Verona. "Vouchsafe me raiment, bed, and food," King Lear begs his daughter Regan. But you needn't turn to Shakespeare to find vouchsafe; today's writers still find it to be a perfectly useful word.

Special Guest J.W. Surface joins us for this episode!Check out J.W.'s book Something Dark and Others here: https://store.bookbaby.com/book/something-dark-and-othersAnd check out Gargoyle Publications here: https://www.etsy.com/shop/GargoylePublicationsProteus was, in Greek legend, Poseidon's herdsman, an old man and a prophet, famous for his power of assuming different shapes at will. The phrase "As many shapes as Proteus" and the adjective "Protean" mean ever-changing, versatile, ready to take on different aspects.Legend says that Proteus lived in a vast cave, and his custom was to count up his herds of sea calves at noon, then to sleep. There was no way of catching him but by stealing upon him at this time and binding him, otherwise he would elude anyone by a rapid change of shape.We here at Radio FreeWrite hope you enjoy this episode.Be sure to follow us on Instagram (if that's your sort of thing). Please do send us an email with your story if you write along, which we hope you will do. Episodes of Radio FreeWrite are protected by a Creative Commons Attribution-NoDerivatives 4.0 International (CC BY-ND 4.0) license. All Stories remain the property of their respective authors.

Sakes alive, we're 35, and in this episode we've been inspired by the recent release of Wanderstop to turn our attention to the nebulous topic of cosy games. Is "cosy" a genre? A theme? A vibe? Are all cosy games broadly the same, or is it just a blanket term that can refer to any game without a central combat mechanic? Is "cosy" even still a valid classification now that we've moved so far past all major new titles being, essentially, Doom with a different paint job? All these questions and more will be debated enthusiastically by the Indieventure trio, even if we entirely lack the ability to form a consensus that provides you with definitive answers. What we can manage, however, is to rattle off a bunch of cosy game recommendations, drawing from personal favourites and cosy classics (and indeed both) to come up with a list that encompasses indie titles as disparate as Stardew Valley (naturally), Chicory: A Colorful Tale, Dorfromantik, Dungeons of Hinterberg, the Frog Detective trilogy, House Flipper 2, Lil' Gator Game, Ooblets, PowerWash Simulator, Proteus, Tangle Tower, Tiny Life, TOEM, Wilmot Works It Out, and Frostpunk (no, really!). We also have a crack at an informal group review of Wanderstop, which has elicited an impressive array of thoughts and opinions among a trio of people who normally tend to kind of agree on most things. Who thought what? You'll have to listen to find out, but I can reveal it's a good chat. (And if you haven't yet listened to the recent Indieventure Extra episode where Liam interviews creators Davey Wreden and Karla Zimonja, here's the link to that!) Finally, as always, we end with our current hyperfixations. Liam is still absolutely caning through an essential catalogue of new and recent game releases, and has this time turned his attention to Monster Hunter Wilds, the latest in Capcom's long-running series about invading the habitats of majestic creatures and turning their hides into some fancy pants. Rebecca is trying to live by Wanderstop's example and be kinder to herself, which mainly involves taking a lot of naps at the moment, but she also throws in a couple of bonus recommendations for anti-burnout narratives in the form of Travis Baldree's high fantasy coffee shop novel Legends & Lattes, and of course the evergreen Pokémon Concierge miniseries. And Rachel's circled back to Mindhack, a dystopian visual novel about neutralising enemies of the state with beautiful electronic flowers that painfully rewire their dissident thoughts. You might remember this one from a couple of years ago, and it's good to see it still steadily making its way through early access, and now including four chapters of a planned eight-slash-nine. Our music was written and performed by Ollie Newbury! Find him on Instagram at @newbsmusic. Meanwhile, you can find us at indieventurepodcast.co.uk or wherever you listen to podcasts, and don't forget that you can now join our dedicated Discord too!

In Shakespeare's Two Gentlemen of Verona, Proteus says “Here's too small a pasture for such store of muttons.” Proteus is speaking metaphorically here, but the phrase refers to the relationship between animals raised in a field, and then processed for food to be stored away in a cache that can be drawed upon for consuming later. Stephano, in the Tempest, shares the location of his store of wine, saying “The whole butt, man: my cellar is in a rock by the sea-side where my wine is hid.” Indicating that a cellar was one place to store bottles of wine long term. Both of these references demonstrate for us that 16th-17th century society was familiar with the idea of storing fresh food for the winter, but it leaves us with the question of what exactly was a “store of muttons,” for example? I mean, Shakespeare and his contemporaries didn't have refrigeration, so what methods were used to keep fresh meat from going rancid? Back with us again this week, to help us understand Tudor and Renaissance England food preservation methods, as well as storage options, like cellars, is our guest and food historian, Neil Buttery.  Get bonus episodes on Patreon Hosted on Acast. See acast.com/privacy for more information.

Marie sits down with Rebecca Robins and Patrick Dunne, authors of Five Generations at work to talk about how to foster better collaboration among a multigenerational workforce. For more Proteus, subscribe to our newsletter: http://conta.cc/43w4LH0

In this special episode of the Healthy Project Podcast, based on questions from the My City My Health conference, host Corey Dion Lewis sits down with Daniel Zinnel, CEO of Proteus, to explore the intersections of health equity, farm worker health, and immigrant health care. They discuss Proteus' innovative programs, including mobile healthcare delivery, health and safety training, cancer prevention efforts, and the critical role of community health workers. Daniel shares insights on addressing health disparities, building impactful partnerships, and creating culturally responsive care for underserved communities. Tune in to discover strategies for supporting migrant worker health and overcoming challenges like mass deportations and healthcare access barriers.Show Notes:[00:01] Introduction to the Healthy Project Podcast and host Corey Deion Lewis[00:24] Special episode overview: My City My Health conference and Ask a Pro platform[01:02] Meet Daniel Zennel, CEO of Proteus, and learn about the organization's history and mission[02:32] Overview of Proteus' services: Job training, education assistance, and health resources[04:25] Health and safety training: Addressing heat stress, pesticide exposure, and farm worker safety[06:02] Mobile healthcare delivery model: Bringing care directly to farm workers[07:18] Health equity in action: The role of farm workers in our daily lives and bridging care gaps[09:25] Supporting immigrant health: Strategies to address diverse community needs[17:29] Translators and AI in healthcare: Balancing technology and human interpretation[22:51] Preparing for mass deportations: Organizational strategies for supporting vulnerable populations[30:02] Cancer prevention initiatives: Focus on breast, cervical, and colorectal screenings[32:40] The importance of partnerships: How collaborations expand public health impact[35:41] Daniel's personal connection to farm worker advocacy and Proteus' mission[38:40] Closing remarks and how to connect with ProteusLinks and Resources:Learn more about Proteus: ProteusInc.netFollow Proteus on social media: LinkedIn, Facebook, Instagram, YouTubeConnect with Daniel Zennel on LinkedIn: Daniel ZennelSupport the Healthy Project Podcast: Like, subscribe, and review to help amplify the conversation!Call to Action:Interested in partnering or supporting? Reach out at hello@healthyprojectmedia.com. Let's push the boundaries of health equity together! ★ Support this podcast ★

Learn more about Proteus: https://proteusmotion.com Follow Proteus on IG: https://www.instagram.com/proteusmotion/